Omnibus proteome-wide association study (PWAS-O) identified 43 risk genes for Alzheimer's disease dementia

Tingyang Hu[1,2], Randy L. Parrish[1,2], Qile Dai[1,2], Aron S. Buchman[3], Shinya Tasaki[3], David A. Bennett[3],

Nicholas T. Seyfried[4], Michael P. Epstein[1], Jingjing Yang[1*]

1. Center for Computational and Quantitative Genetics, Department of Human Genetics, Emory

University School of Medicine, Atlanta, GA, 30322, USA

2. Department of Biostatistics and Bioinformatics, Emory University School of Public Health, Atlanta,

GA, 30322, USA

3. Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, 60612, USA

4. Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, 30322, USA

* Correspondence Author: jingjing.yang@emory.edu

Abstract

Proteome-wide association study (PWAS) integrating proteomics data with GWAS data is a powerful tool
to identify risk genes for complex diseases, which can inform disease mechanisms with genetic effects
mediated through protein abundance. We propose a novel omnibus method to improve PWAS power by
modeling unknown genetic architectures with multiple statistical models. We applied TIGAR, PrediXcan,
and FUSION to train protein abundance imputation models for 8,430 proteins from dorsolateral prefrontal
cortex with whole genome sequencing data (n=355). Next, the trained models were integrated with
GWAS summary data of Alzheimer's disease (AD) dementia (n=762,917) to conduct PWAS. Last, we
employed the Aggregated Cauchy Association Test to obtain omnibus PWAS (PWAS-O) p-values from
these three models. PWAS-O identified 43 risk genes of AD dementia including 5 novel risk genes that
were interconnected through a protein-protein interaction network including *TOMM40*, *APOC1*, and
APOC2. PWAS-O can be easily applied to study complex diseases.

Introduction

Recent large-scale genome-wide association studies (GWAS) of Alzheimer's disease (AD)

dementia have identified 38 risk loci[1], but little is known about their underlying mechanisms. Integrating

transcriptomic data with GWAS data through transcriptome-wide association study (TWAS) has been

shown an effective approach for identifying potential causal risk genes of complex human diseases with

biological interpretations[2-4]. TWAS can inform potential underlying disease mechanisms as the identified

genetic effects may be potentially mediated via gene expression[5, 6]. Since many biological processes can

affect protein abundance, gene expression levels might not be the optimal proxy for elucidating the role of

proteins in disease mechanisms. The analogous proteome-wide association study (PWAS) approach

integrating proteomic data with GWAS summary data[7-9] has the potential to identify novel genetic risk

loci linked to disease via proteins that may be missed by GWAS and TWAS[2-4, 10].

Since gene expression and protein abundance are both molecular quantitative traits that might

mediate genetic effects, existing TWAS tools can be used for PWAS. TWAS tools can train protein

abundance imputation models using genetic variants as predictors from a reference panel with both

proteomic and genetic data available. Analogously, genetic effect sizes in the imputation models could be

viewed as effect sizes of "protein quantitative trait locus (pQTL)" in a broad sense (as these "pQTL" are

not necessarily statistically significant), which would be taken as variant weights for gene-based

association study (i.e., PWAS) with GWAS data.

Existing TWAS tools use various statistical regression models to train imputation models of

quantitative molecular traits, and each tool has its own advantage for modeling a specific type of genetic

architecture underlying the molecular trait of interest. For example, PrediXcan[11] uses a penalized linear

regression model with Elastic-Net penalty[12] which has the advantage of modeling sparse genetic

architectures. TIGAR[2] implements the nonparametric Bayesian latent Dirichlet process regression (DPR)

which has been shown effective to model the infinitesimal genetic architecture[13]. FUSION[5] uses

penalized linear regression model with Elastic-Net penalty and LASSO penalty[14], regular linear

regression model with best unbiased linear predictor (BLUP), single variant model with Top eQTL or

pQTL (Top1), and Bayesian spare linear mixed model (BSLMM)[15], and then selects the best model for

gene-based association study based on cross-validation (CV) R^2 of these multiple models.

Even though the FUSION tool employs multiple statistical models, it only uses the model with

top performance based on reference data. Rather than selecting a single statistical method to estimate

molecular QTL weights, previous study[16] have shown that combining association test p-values based on

multiple statistical methods using the Aggregated Cauchy Association Test[17] (ACAT) can increase power

while controlling for type I error. Therefore, we apply ACAT to aggregate PWAS p-values obtained by

TIGAR, PrediXcan, and FUSION, which subsequently obtain an omnibus PWAS (PWAS-O) p-value.

PWAS-O is expected to improve PWAS power compared to PWAS based on a single imputation model

of protein abundances, as PWAS-O better accounts for the unknown genetic architecture of protein

abundances with multiple statistical models.

To evaluate the performance of PWAS-O, we conducted simulation studies using real genetic

data based on patterns observed in real PWAS. We showed that PWAS-O outperformed all three

individual methods with well calibrated type I error. We then applied PWAS-O to study AD dementia by

using the reference human proteome-wide data of dorsolateral prefrontal cortex (DLPFC) of 355 older

decedents with whole genome sequencing (WGS) genetic data, and summary data from the most recent

GWAS of AD dementia (n=762,917, excluding 23&me samples)[1]. Next, we examined the protein-protein

interaction (PPI) network among the identified PWAS risk genes of AD dementia. We identified 43 risk

genes of AD dementia by PWAS-O that were connected through a protein-protein interaction (PPI)

network involving the well-known risk genes of AD dementia. We validated the potential causality of 27

out of 43 (63%) PWAS risk genes by probabilistic Mendelian randomization (PMR-Egger)[18] and

summary data-based Mendelian randomization (SMR)[19, 20] tool.

76
77   **Results**
78
79   **<u>Omnibus PWAS (PWAS-O)</u>**
80

Similar to the standard two-stage PWAS/TWAS method (**Methods; Fig. 1**)[11, 21], protein

abundance imputation models are first trained in Stage I to obtain estimated effect sizes of genetic

variants/predictors (i.e., pQTL weights), by TIGAR[21] (nonparametric Bayesian DPR), PrediXcan[11]

(Elastic-Net), and FUSION[5] (Elastic-Net, LASSO, BLUP, Top1). Genetic variants within ±1MB around

the transcription starting and termination sites of the corresponding coding gene were considered as

predictors in the imputation models. In Stage II, these trained pQTL weights (coefficients of these genetic

variant predictors) are used as variant weights along with GWAS data to conduct gene-based association

tests. For each protein-coding gene, PWAS p-values will be respectively obtained by using the pQTL

weights estimated by TIGAR, PrediXcan, and FUSION, which will then be combined by ACAT to

generate the corresponding PWAS-O p-value (**Methods**). We present the PWAS-O framework in **Fig. 2**.

Both individual-level and summary-level GWAS data can be used in Stage II. A reference panel of the

same ancestry as the GWAS data can be used to provide LD information for gene-based association tests

in Stage II. The TIGAR[21] tool provides functions to calculate LD covariance matrices and conduct gene-

based association tests.

Simulation Study

Simulation studies were conducted to evaluate the performance of PWAS-O method. We use the

real genotype data from 1894 whole genome sequencing (WGS) samples from the Religious Orders

Study/Memory and Aging Project (ROS/MAP)[22] and Mount Sinai Brain Bank (MSBB)[23] study to

simulate protein abundance data. We randomly selected 500 protein-coding genes with various gene

length, and split samples into 568 training (30%) and 1326 testing (70%) samples to mimic a sample size

in real reference panels for training protein abundance imputation models. We considered 4 different

scenarios consisting of 2 proportions of causal cis-pQTL, $p_{causal} = (0.001, 0.01)$, and 2 proportions of

protein abundance variance attributed to causal pQTL, $h_p^2 = (0.01, 0.05)$.

We generated protein abundance (E_p) from the multivariable regression model $E_p = \mathbf{X}_g \mathbf{w} + \boldsymbol{\epsilon}_g$,

using genotype matrix $\mathbf{X}_g$ of the randomly selected causal pQTL of protein p, $\boldsymbol{\epsilon}_g \sim N(0, (1 - h_p^2)\mathbf{I})$. For

each protein-coding gene, we generated 10 replicates of pQTL effect sizes $\mathbf{w}$ from $N(0,1)$ per scenario,

and rescaled these effect sizes to ensure the protein expression variance explained by causal variants is

h_p^2. For each scenario, a total of 5000 replicates of protein traits were generated for selected 500 protein-

coding genes. We then generated GWAS Z-scores from a multivariate normal distribution with $\mathbf{Z} \sim$

$MVN\left(\boldsymbol{\Sigma}_g \mathbf{w} \sqrt{n_{gwas} h_{pheno}^2}, \ \boldsymbol{\Sigma}_g\right)$ [24], where $\mathbf{w}$ denotes the true causal pQTL effect sizes, $\boldsymbol{\Sigma}_g$ is the

correlation matrix of genotype $\mathbf{X}_{test}$ for testing samples, and n_{gwas} denotes GWAS sample size. We set

$h_{pheno}^2 = 0.025$, denoting the amount of phenotypic variance explained by simulated genetically

regulated protein abundance $\mathbf{X}_g \mathbf{w}$. We considered $n_{gwas} = (25K, 50K, 75K, 100K)$ for scenarios with

$h_p^2 = 0.05$ and $n_{gwas} = (600K, 800K, 1000K, 1200K)$ with $h_p^2 = 0.01$. We generated 10 replicates of

GWAS Z-scores per simulated protein trait per gene, resulting in a total of 50,000 PWAS simulation

replicates.

In stage I of PWAS simulation analysis, we applied TIGAR, PrediXcan and FUSION to estimate

pQTL weights from simulated protein traits of 568 training samples. In stage II, we integrated estimated

pQTL weights with simulated GWAS Z-scores to conduct gene-based association tests. We further

combined PWAS p-values obtained by these 3 tools using ACAT to generate PWAS-O p-values. We

evaluated the training performance of these 3 individual methods by calculating the squared Pearson

correlation coefficient between imputed genetically regulated protein abundances and simulated protein

traits of 1326 testing samples, which was referred as test R^2. PWAS power was given by the proportion of

50,000 repeated simulations with PWAS p-value value $< 2.5 \times 10^{-6}$ (genome-wide significance

threshold for gene-based association test). We compared PWAS power by PWAS-O to all 3 individual

methods.

We showed that optimal test R^2 and PWAS power based on one statistical model (**Fig. 3**) depended

on the underlying genetic architecture of protein abundance (p_{causal}) and protein heritability (h_p^2). When

protein heritability was small ($h_p^2 = 0.01$), PrediXcan had the lowest test R^2 and power. When protein

heritability increased ($h_p^2 = 0.05$) with sparse true cis-pQTLs ($p_{causal} = 0.001$), PrediXcan became the

optimal method with highest test R^2 and power. For a less sparse model with $p_{causal} = 0.01$, FUSION

generally performed best among the individual methods. We found that PWAS-O obtained the highest

power across all the scenarios by combining the PWAS p-values based on 3 methods.

We also evaluated type I errors of these individual methods and PWAS-O under one simulated

scenario with $h_p^2 = 0.05$ and $p_{causal} = 0.001$. We simulated 2×10^3 phenotype from $N(0,1)$ for each of

the 500 genes and permuted estimated pQTL weights to conduct a total of 10^6 null simulations. Both

individual methods and PWAS-O showed well calibrated type I errors, as shown by quantile-quantile (Q-

Q) plots of p-values (**Fig. S1**).

ROS/MAP Proteomics and WGS data

The human brain proteomic reference data used in the PWAS-O application study of AD

dementia in this study were profiled from the DLPFC of postmortem brain samples donated by 400

participants of European ancestry of the Religious Orders Study and Memory and Aging Project

(ROS/MAP)[7, 22]. These human proteome abundance data underwent quality control (**Methods; Fig. S2**)

that regressed out the effects of technical factors and confounding covariates including age at death, sex,

postmortem interval, and study (ROS or MAP). Proteome abundance data of 8,430 proteins of 355

individuals who also had WGS data profiled[25] were obtained after quality control and used as reference

data in the PWAS-O application study of AD dementia in this study. This ROS/MAP reference proteomic

data set is one of the largest available proteomic data sets for DLPFC tissue which is a relevant tissue for

studying AD dementia.

PWAS-O results of studying AD dementia

At training Stage I, five-fold cross-validation was conducted to evaluate the training performance

per statistical model. The protein abundance imputation models with 5-fold CV R^2 >0.5% were retained

and their estimated pQTL weights were used to conduct PWAS. As suggested by the TIGAR tool[21], the

threshold of 5-fold CV R^2 >0.5% was arbitrarily chosen to allow a greater number of protein-coding

genes to be tested by the follow-up gene-based association study (i.e., PWAS). The threshold of CV R^2

would not affect the statistical validity of the test statistic used in the follow-up PWAS.

As shown in **Table 1**, 6,673 protein abundance imputation models were retained by TIGAR with

median CV R^2 = 0.013; 1,835 protein abundance imputation models were retained by PrediXcan with

median CV R^2 = 0.0094; and 2,173 protein abundance imputation models were retained by FUSION (the

best model selected out of LASSO, Elastic-Net, BLUP, Top1 models with the highest CV R^2) with

median CV R^2 = 0.0093. Histograms of the CV R^2 obtained by these three tools were presented in **Fig.**

S3.

As described in the above about the PWAS-O framework, we first conducted PWAS by

employing TIGAR[21], PrediXcan[11], and FUSION[5] tools, using the ROS/MAP reference proteomics data of

DLPFC and the most recent GWAS[1] summary data of AD dementia (n=762,917, excluding 23&me

samples; **Methods**). That is, the estimated pQTL effect sizes in the retained protein abundance imputation

models by these three tools were taken as variant weights to conduct gene-based association tests along

with GWAS summary data of AD dementia (**Fig. S4**). Second, we implemented ACAT[17] to obtain

PWAS-O p-values from the PWAS p-values by these three tools. Q-Q plots of PWAS-O and PWAS

results of AD dementia by these three tools were presented in **Fig. S5**.

Our PWAS-O approach identified 43 significant genes with false discovery rate (FDR) (i.e., q-

value) <0.05, which could affect the risk of AD dementia through their genetic effects on the

corresponding protein abundances (**Fig. 4**). We curated 19 independent genes from these 43 significant

genes (**Table 2; Table S1**), by considering only the most significant genes among all significant genes

with shared test regions (±1MB around the test transcription starting and termination sites of the protein-

coding gene). In particular, we found all individual methods contributed to the PWAS-O results (**Table 2;**

Table S1; Fig. S6). Out of 43 PWAS risk genes, 33, 9, and 7 genes were detected by TIGAR, FUSION,

and PrediXcan, respectively.

We found 10 out of these 43 PWAS risk genes were detected by previous GWAS studies of AD

as shown in GWAS Catalogue[26], including *AGFG2*[27]*, CLPTM1*[28]*, PVR*[28]*, PVRL2*[28]*, APOC1*[29]*, APOC2*[30]*,*

CKM[28]*, ERCC1*[31]*, OPA3*[31]*,* and *SYMPK*[31]*.* PWAS risk genes *CDC42*[32]*, MAP3K7*[33]*,* and *FNBP4*[32] were

found associated with cognitive ability in previous GWAS studies. PWAS risk genes *CCDC86*[34]*,*

KIF18B[34]*, PPM1N*[34]*,* and *RTN2*[34] were previously found associated with neurofibrillary tangles

measurement (a key clinical indicator of AD) by GWAS studies. Additionally, 13 out of 43 significant

AD PWAS genes (*ZYX*[35]*, C1QTNF4*[36]*, FNBP4*[35]*, PVR*[3]*, PVRL2*[36]*, TOMM40*[3]*, APOC1*[4]*, APOC2*[37]*,*

CLPTM1[36]*, ERCC1*[38]*, OPA3*[38]*, EML2*[4] and *DMWD*[35]) were significant risk genes of AD by previously

published TWAS.

Our PWAS-O findings not only replicated significant risk genes identified by previous GWAS

and TWAS, but also identify novel risk genes for AD dementia. PWAS-O identified 5 novel risk genes

that were neither detected by GWAS nor TWAS (*MGAT5, PACSIN3*, *PLA2G7, DIABLO, YWHAB*). The

novel gene *PLA2G7* was shown to have biological function involved in inflammatory and oxidative

activities[39], with a known association with AD and cognitive decline[40]. The novel gene *PACSIN3* has

been implicated in the disorders of the central nervous system such as schizophrenia[41].

pQTL weights by different regression models

To investigate the genetic architecture underlying protein abundances, we plotted the pQTL

weights estimated by TIGAR (DPR), PrediXcan (Elastic-Net), and FUSION (best model out of LASSO,

Elastic-Net, BLUP, Top1) for significant PWAS risk genes *PPM1N* and *DCAKD* in **Fig. 5**. Generally,

TIGAR and FUSION had non-zero pQTL weights estimated for almost all test SNPs within the test

region, for using a model assuming infinitesimal genetic architecture[13]. Whereas, PrediXcan had much

fewer non-zero pQTL weights estimated for assuming a sparse genetic architecture and enforcing variable

selection. For example, *PPM1N* was a significant risk gene identified by both TIGAR and FUSION

(**Table 2**), which has hundreds of test SNPs with non-zero pQTL weights (by both TIGAR and FUSION)

that were colocalized with significant GWAS signals (colored dots in **Fig. 5A**). Gene *DCAKD* was only

found significant by FUSION (p-value = 3.12×10^{-5}) but not by TIGAR (p-value = 3.62×10^{-3}), for

having fewer test SNPs of relatively large magnitude of pQTL weights that were colocalized with

significant GWAS signals (**Table2, Fig. 5B**).

Similarly, comparing pQTL weights obtained by TIGAR to PrediXcan for significant PWAS

genes *MBLAC1* and *MRPL16* (**Fig. S7**), we observed that less than 10 test SNPs had non-zero pQTL

weights by PrediXcan, versus thousands of test SNPs with non-zero pQTL weights by TIGAR. Because

PrediXcan estimated zero pQTL weights for most SNPs with significant GWAS p-values in the test

region of gene *MRPL16* (**Table 2**, **Fig. S7A**), *MRPL16* was only found significant by TIGAR (p-value =

4.33×10^{-15}), but not by PrediXcan (p-value = 1.31×10^{-2}). Whereas, when both TIGAR and

PrediXcan estimated non-zero pQTL weights for SNPs with significant GWAS p-values in the test region

of gene *MBLAC1* (**Table S1, Fig. S7B**), it was identified significant by both TIGAR (p-value =

7.31×10^{-5}) and PrediXcan (p-value = 3.49×10^{-4}).

These scatterplots of pQTL weights of PWAS risk genes showed that significant PWAS genes

were mainly driven by test SNPs that had non-zero pQTL weights colocalized with significant GWAS

signals. Because the underlying genetic architectures of protein abundances are complicated and unknown

in practice, no single statistical model would lead to superior PWAS power across genome-wide protein-

coding genes. Our proposed PWAS-O approach is expected to gain power in practice for considering

multiple statistical models per protein.

PPI network among PWAS risk genes of AD dementia

Next, we used STRING[42, 43] to investigate the PPI network among these 43 PWAS risk genes of

AD dementia, by using public data sources of known protein-protein interactions including evidences

from curated databases, experiments, text mining, co-expression, gene fusions, and protein homology[42]

(**Methods**). STRING clustered 23 out of these 43 PWAS risk genes into 4 communities (**Fig. 6**), where

different data sources of the protein-protein connection were depicted by differently colored connection

edges. It is interesting to see that the largest community of these PWAS risk genes is a network involving

genes *TOMM40*, *APOC1*, and *APOC2* that are located nearby the well-known risk gene *APOE* of AD

dementia, and are known to be associated with both AD dementia and low-density lipoprotein levels[44].

STRING also provided gene enrichment analysis results with respect to Gene Ontologies (GO)

and KEGG pathways. We observed that these 43 PWAS risk genes were enriched for the GO terms of

UV protection (*ERCC1, ERCC2, ERCC3*) with FDR = 0.010, transcription-coupled nucleotide-excision

repair (*ERCC1, ERCC2, ERCC3, PRPF19*) with FDR = 0.013, plasma lipoprotein particle remodeling

(*APOC1, APOC2, PLA2G7*) with FDR = 0.014, negative regulation of very-low-density lipoprotein

particle clearance (*APOC1, APOC2*) with FDR = 0.018, protein-containing complex subunit (*MRPL16,*

ATPAF2, KIF18B, ERCC2, ERCC3, PRPF19, APOC1, APOC2, PLA2G7) with FDR = 0.026, and the

KEGG pathway of adherens junction (*MAP3K7*, *CDC42*, *PVRL2*) with FDR = 0.012.

Interestingly, novel PWAS risk genes *ERCC3*, *ERCC2* and *PRPF19* are closely interconnected

with a known GWAS/TWAS risk gene *ERCC1* in the PPI network and enriched in nucleotide-excision

repair pathway. Novel PWAS risk gene *PLA2G7* connects with *APOC1* and *APOC2* in the PPI network

and involves in the plasma lipoprotein particle remodeling pathway.

These PPI network analysis results showed that the list of identified risk genes by PWAS-O were

connected with known risk genes of AD dementia and enriched in AD related pathways.

<u>Examine causal and pleiotropy effects of PWAS risk genes</u>

We applied both probabilistic Mendelian randomization (PMR-Egger)[18] and summary data-based

Mendelian randomization (SMR) methods to test if the causal genetic effects on AD dementia were

mediated through protein abundance in the possible presence of horizontal pleiotropy (**Methods**).

Horizontal pleiotropy means that genetic effects on AD dementia and on protein abundances originated

from the same SNPs but through different pathways (i.e., with no mediation effects). PMR-Egger

suggested that 25 out of 43 PWAS risk genes have significant causal effects (FDR<0.05) on AD dementia

after controlling for potential horizontal pleiotropy effects, including 6 genes (*PVRL2, TOMM40, APOC1,*

RTN2, OPA3, EML2) nearby the *APOE* region that also have significant horizontal pleiotropy effects with

FDR<0.05. Similarly, the method of SMR with its accompanying heterogeneity in dependent instruments

(HEIDI) test found that 22 out of 43 PWAS risk genes have potential causal effects on AD dementia with

FDR<0.1, of which 20 genes were overlapped with 25 causal genes detected by PMR tool. These results

validated potential causal genetic effects that were mediated through protein abundances for 27 (63%)

PWAS risk genes identified by PWAS-O (**Table 2; Table S1**).

Compare with TWAS results of AD dementia

To determine whether the 43 PWAS risk genes had similar evidence at the transcript level, we

also conducted TWAS of AD dementia using ROS/MAP transcriptomic reference data of DLPFC tissue

and the same GWAS summary data of AD dementia by TIGAR and PredXican. From TWAS p-values by

these two tools, we obtained omnibus TWAS (TWAS-O) p-values by ACAT (**Methods**). We found that

34 out of 43 PWAS risk genes (79%) were either detected by TWAS-O or located within 1MB of the

transcription starting sites and termination sites of the significant risk genes by TWAS-O with FDR<0.05

(**Table S2, Fig. S8**). These results showed that the majority of PWAS risk genes had genetic effects on

phenotype that were mediated through both transcriptome and proteome.

Discussion

In this work, we propose an omnibus PWAS approach (PWAS-O) that improves power for better

modeling of the unknown genetic architecture of proteome abundances by multiple statistical models. By

aggregating PWAS p-values obtained from several available tools (i.e., TIGAR, PrediXcan, and

FUSION) that used different statistical models, our PWAS-O approach improves power over using one

individual tool. Our simulation studies showed that the performance of each of these three tools depended

on the underlying genetic architecture for protein abundance and protein heritability. We found PrediXcan

performed better for sparse architecture and higher heritability, whereas TIGAR and FUSION had better

performance for denser architecture. PWAS-O was demonstrated with optimal performance across all

considered simulation scenarios with well calibrated type I error. Since the genetic architecture of protein

abundance is unknown, the practical use of PWAS-O is well justified.

By using the ROS/MAP reference proteomic data and the most recent GWAS summary data of

AD dementia, PWAS-O identified 43 risk genes of AD dementia. All three individual methods

contributed to the PWAS-O results. Notable biological roles were shown by previous studies for these

identified PWAS risk genes include lipoprotein metabolism, inflammatory reactions, DNA repair, pre-

mRNA splicing, and mitochondrial function. For example, *APOC1* and *APOC2*, located in a gene cluster

on chromosome 19 including the well-known AD risk gene *APOE*[45, 46], play important roles in the

development of lipoprotein metabolism[44]. Especially, *APOE* is an intensively studied risk gene of AD and

plays an essential role in the central nervous system[47, 48]. Connected with *APOC1* and *APOC2,* as shown

in the PPI of our identified PWAS risk genes, *PLA2G7* is a novel AD risk gene identified by PWAS-O

and associated with inflammatory oxidative activities, and has been implicated in cognitive impairment

and AD[39].

Additionally, *ERCC1, ERCC2,* and *ERCC3* are involved in nucleotide excision repair pathway

contributing to genome stability[49, 50], which plays a critical role during the development of the central

nervous system[51] and whose impairment is associated with AD[52]. Gene *PRPF19* that is interconnected

with *ERCC1, ERCC2*, and *ERCC3* encodes a pre-mRNA processing factor involved in regulating pre-

mRNA splicing[53]. Prior studies indicated that *PRPF19* had a neuronal function and was implicated in

neurological diseases[54, 55]; lower expression level of gene *MRPL16* encoding a mitochondrial ribosome

protein was observed in AD blood cells which may reflect a general response to inflammatory

environment in AD[56]; gene *ATPAF2* connected with *MRPL*16 encodes a protein involved in

mitochondrial function and lipid pathway, which has been implicated in dementia pathogenesis[57].

By STRING analysis, we showed that out of these 43 PWAS significant risk genes, 9 genes were

enriched in the pathway of protein-containing complex subunit; 4 genes were enriched in the gene

ontology pathway of transcription-coupled nucleotide-excision repair; 3 genes were enriched in the

pathway of plasma lipoprotein particle remodeling. Compared to TWAS-O results using the same GWAS

summary data, 34 out of 43 significant PWAS risk genes were either TWAS-O risk genes or within 1MB

test region of TWAS risk genes. These results showed that PWAS risk genes identified by our PWAS-O

approach are part of key biological pathways involving brain functions. The genes and proteins identified

may be high-value therapeutic targets for further drug discovery as well as for mechanistic studies that

can advance our understanding of the biology driving AD dementia in aging brains.

PWAS-O still has its limitations. First, the CV R^2 is generally low for majority protein

abundance prediction models. This might be due to small sample sizes in the reference proteomic data, or

low heritability of protein abundances due to cis-SNPs. Only *cis*-SNPs within the $\pm 1MB$ region around

the transcription starting and termination sites of the corresponding protein-coding gene were considered

as predictors for protein abundances by PWAS-O. Trans-SNPs could also be considered as additional

predictors in the protein abundance prediction models, which might increase the CV R^2 of protein

abundance imputation models but will be subject to high computation burden[3]. Second, the standard two-

stage PWAS method cannot distinguish whether causal SNPs for the phenotype of interest are only

colocalized with pQTLs but have no mediation effect through the protein abundances (i.e., horizontal

pleiotropy) or indeed have genetic effects mediated by protein abundances (i.e., vertical pleiotropy).

Horizontal pleiotropy happens when genetic variants impact the outcome through pathways different from

or additional to the proteome abundances of the test gene[58]. Here, we applied PMR-Egger[18] and SMR[59]

tool to test the causal effects of 43 PWAS risk genes while controlling for horizontal pleiotropy. We

validated the potential causality 27 genes out of 43 genes identified by our PWAS-O. Third, a cluster of

significant PWAS risk genes are likely to be identified as shown in the locus around *APOE* for AD

dementia for sharing test SNPs in the overlapped test gene region. Even though the PMR-Egger and SMR

tools provide some insights into the potential causality/mediation role of the genetically regulated protein

abundances for the phenotype of interest, true causal genes will still need to be replicated by further

biological experiments.

In summary, PWAS-O represents the first omnibus PWAS method that increases power by

leveraging multiple statistical models. PWAS-O can be easily applied to integrating reference proteomic

data with publicly available large-scale GWAS summary data, for studying complex polygenic diseases.

We believe that PWAS-O would be useful for mapping risk genes with genetic effects potentially

mediated through proteome abundances for complex diseases. Identified PWAS risk genes would shed

light upon future studies of disease pathogenesis and therapeutics.

343
344 **Methods**
345
346 **Two-stage PWAS**
347
As shown in **Fig. 1**, the two-stage PWAS first trains protein abundance imputation models (Stage

I) by taking *cis*-genotype data, ±1MB around the transcription starting and termination sites of the

corresponding protein-coding gene, as predictors (X), protein abundance level ($\mathbf{E}_p$) as the outcome, as

shown in the following linear regression model:

$$\mathbf{E}_p = \mathbf{Xw} + \boldsymbol{\epsilon}; \ \boldsymbol{\epsilon} \sim N(0, \sigma_\epsilon^2 \mathbf{I}).$$

The effect size vector $\mathbf{w}$ could be estimated by different statistical models as employed by TIGAR[21],

PrediXcan[11], and FUSION[5], which could be viewed as a broad sense of pQTL effect sizes (also referred

to as pQTL weights). Specifically, PrediXcan employs a penalized linear regression model with Elastic-

Net penalty[11]; FUSION[5] uses penalized linear regression model with Elastic-Net penalty and LASSO

penalty[14], regular linear regression model with best unbiased linear predictor (BLUP), single variant

model with Top pQTL (Top1), and Bayesian spare linear mixed model (BSLMM)[15], and then selects the

best model according to CV R^2; TIGAR[2] implements the nonparametric Bayesian latent DPR model.

In Stage II, with individual-level GWAS data, the protein abundances will first be imputed by

using the trained imputation models and individual-level genotype data of test samples. Then PWAS will

test the association between the imputed protein abundances and the phenotype of interest. With summary

GWAS data, PWAS would take the pQTL weights estimated in Stage I as variant weights to conduct

gene-based association test with GWAS Z-scores and reference LD, which has been shown to be

equivalent as testing the association between imputed genetically regulated protein abundances and the

phenotype of interest[60]. That is, the PWAS test is equivalent to a burden test with the following test

statistic:

368
$$\tilde{Z}_{p,S\text{-}PrediXcan} = \frac{\sum_{l=1}^{m}(\widehat{w}_l\widehat{\sigma}_l Z_l)}{\sqrt{\widehat{\mathbf{w}}'\mathbf{V}\widehat{\mathbf{w}}}}, \quad \widehat{\sigma_l^2} = \mathrm{Var}(\mathbf{X_{0,l}}), \quad \mathbf{V} = \mathrm{Cov}(\mathbf{G_0}).$$

Here, $\widehat{w}_l$ denotes the pQTL effect size estimates from protein imputation models; Z_l denotes the Z-score

statistics of single variant l by GWAS; and $\mathbf{V}$ denotes the LD covariance matrix from a reference panel of

the same ancestry as the test GWAS cohort. The genotype variance $\widehat{\sigma}_l$ of test SNPs can also be estimated

from a reference panel of the same ancestry as the test cohort.

<u>PWAS-O Method</u>

As shown in **Fig. 2**, with PWAS p-values obtained by two-stage PWAS tools including TIGAR[21],

PrediXcan[11], and FUSION[5], PWAS-O uses ACAT[17] to aggregate these three PWAS p-values to generate

an omnibus test p-value per protein-coding gene. The ACAT test statistic is given by

379
$$T = \frac{1}{K}\sum_{k=1}^{K}\tan\{(0.5 - p_k)\}\pi\}, \quad \pi \approx 3.14;$$

380   where p_k is the PWAS p-value obtained by standard two-stage PWAS tools. Under null hypothesis, the p-

381   value p_k is uniformly distributed in $[0, 1]$ and the transformation $\tan\{(0.5 - p_k)\}$ is Cauchy distributed.

382   Thus, the null distribution of the test statistic T can be approximated by a Cauchy distribution[18] and the

383   corresponding PWAS-O p-value can be approximated by

$$pvalue_T \approx \frac{1}{2} - \frac{\{\arctan(T)\}}{\pi}, \qquad \pi \approx 3.14.$$

ROS/MAP Proteomics and WGS Data

Human brain proteomic profiles were generated from the dorsolateral prefrontal cortex (DLPFC) of postmortem brain samples donated by 400 participants of European ancestry of the Religious Orders Study or Rush Memory and Aging Project (ROS/MAP)[7, 22] . Participants in ROS and MAP enroll without known dementia and agree to annual clinical evaluation and organ donation at death. All participants sign an informed consent, Anatomic Gift Act and Repository Consent. Both studies were reviewed by an Institutional Review Board of Rush University Medical Center. Age was calculated from birth date and date of death. Sex was self-reported. Protein measurements from DLPFC were quantified by tandem mass spectrometry.

As described in previous publication[61], protein abundances were normalized by scaling each protein abundance with respect to a sample-specific total protein abundance, and proteins with missing values in more than 50% of the participants were excluded from the analyses. Protein abundance ratios related to baseline (sample-specific total protein abundance) were $\log_2$ transformed, with missing values imputed by the corresponding mean in the cohort. Confounding covariates of clinical characteristics including sex, age at death, postmortem interval, and study type (ROS or MAP), as well as technical factors including sequencing batch and MS2 versus MS3 mass spectrometry reporter quantification mode, were regressed out from protein abundances. Outlier samples were removed using iterative principal component analysis (PCA) as shown in **Fig. S2**. That is, samples with one of the top 2 principal components (PCs) greater than the corresponding four times of the standard deviations from the mean of the corresponding PC[61].

The genotype data of ROS/MAP samples were profiled by whole genome sequencing (WGS)[25]. SNPs with Hardy-Weinberg equilibrium p-values $<10^{-5}$ and minor allele frequency >1% were used as genetic predictors for training the protein abundance imputation models. After quality control of both

proteomic and genetic data, a total of 355 samples with both proteomic and WGS data were used as the

reference data for the application study of PWAS-O in this study.

Summary-level GWAS data of AD dementia

The summary-level GWAS data of AD dementia (i.e., single variant Z-score test statistics

obtained by meta-analysis) were generated by the latest GWAS by Wightman et al[1], including 762,917

individuals from 12 cohorts except 23&Me samples. About 11.3% of participants had clinically

diagnosed AD dementia.

PWAS of AD dementia

In this study, we used the ROS/MAP proteomics and WGS data of 355 samples as reference data

to train protein abundance imputation models. For each protein, we first used TIGAR tool to train

nonparametric Bayesian DPR model and Elastic-Net regression model (as used by PrediXcan), and then

used FUSION[5] tool to train LASSO, Elastic-Net, BLUP, and Top1 models and then selected the best

model according to the CV R^2. We did not train a BSLMM model due to its high computation cost for

WGS data, and we expect that the nonparametric Bayesian DPR model would account for the mixed

sparse and infinitesimal genetic architecture. The 5-fold CV was conducted for all protein abundance

imputation models. The average CV R^2 across 5 folds of validation data per protein was used to select the

best performing FUSION model as well as filter protein abundance imputation models for the follow-up

PWAS.

Second, protein abundance imputation models with 5-fold CV R^2 >0.005 were considered as

valid, and the corresponding pQTL weights were used along with summary-level GWAS data of AD

dementia to test for PWAS risk genes[21]. Last, PWAS-O p-values were generated by aggregating PWAS p-

values obtained by using pQTL weights estimated by TIGAR (DPR), PrediXcan (Elastic-Net), and

FUSION (best model) by ACAT.

PPI network and pathway analysis

To investigate the PPI network among the identified PWAS risk genes of AD dementia, we used

STRING[42, 43], a website for PPI network analysis which integrates public data sources of protein

interaction information and investigates the connectivity network of proteins. Proteins are considered as

nodes in the PPI network. Protein-protein edges represent the predicted functional associations, colored

differently to indicate seven categories — co-expression, text-mining, experiments (biochemical/genetic

data), databases (previously curated pathway and protein complex information), gene co-occurrence, gene

fusion and neighborhood. Gene co-occurrence, fusion, and neighborhood represent association

predictions are based on whole-genome comparisons.

STRING also enables gene-set enrichment analysis with respect to Gene Ontology (GO)

annotations[62], KEGG pathways[63], Reactome pathways[64], and UniProt keywords[65]. Enrichment analysis is

to detect GO terms, pathways, or UniProt keywords that are significantly enriched with genes in the

network versus random genes, adjusting for FDR. STRING also shows significant association between

input proteins and human phenotypes based on Monarch Initiative[66], a system to organize genotype-

phenotype connections from multiple data sources.

Test causal and pleiotropy effects

We used the PMR-Egger[18] tool to test the vertical pleiotropy effect (i.e., causal mediation effect)

between the protein abundance level of PWAS risk genes and AD dementia, while controlling for

horizontal effect. The Multi-SNP-based SMR[59, 67] software and its accompanying heterogeneity in

dependent instruments (HEIDI) were also implemented to test the causal effect, using multiple *cis*-pQTL

SNPs. Reference LD derived from ROS/MAP WGS data were used to implement both PMR-Egger and

SMR-HEIDI methods. Test cis-SNPs were pruned according to their LD correlation matrix. The threshold

of $R^2 = 0.95$ was used for implementing PMR-Egger and $R^2 = 0.99$ was used for implementing SMR-

HEIDI. For each protein-coding gene, only SNPs that have nominal eQTL p-value < 0.05 were tested by

SMR-HEIDI.

<u>TWAS-O of AD dementia</u>

TWAS p-values were first obtained by using reference transcriptomic data of DLPFC tissue from

ROS/MAP samples and GWAS summary data of AD dementia by TIGAR and PrediXcan, and then used

to derive TWAS-O p-values by ACAT. The same GWAS summary data of AD dementia were used in

both PWAS-O and TWAS-O analysis in this study. The reference transcriptomic data include 465

ROS/MAP samples with both gene expression data for DLPFC tissue (by RNA sequencing) and WGS

genotype data profiled. Gene expression data in the format of Transcripts Per Million (TPM) were log2

transformed and adjusted for age at death, sex, postmortem interval, study (ROS or MAP), batch effects,

RNA integrity number scores, estimated cell type proportions (with respect to oligodendrocytes,

astrocytes, microglia, neurons), top five genotype PCs, and top probabilistic estimation of expression

residuals (PEER) factors by linear regression models. The cell type proportions were estimated by using

CIBERSORT pipeline[68] with single-cell RNA-seq transcriptome profiles from human brain tissues as the

reference[69] to de-convolute bulk RNA-seq data[70]. Only genes with >0.1 TPM in ≥10 samples were

considered. Cis-SNPs within a 1MB window of each gene that met the MAF threshold >1% and Hardy-

Weinberg Equilibrium (HWE) threshold of p-value>10^{-5} were used in the imputation model as predictors.

Only genes with an average 5-fold cross validation $R^2 \geq 0.005$ in the gene expression imputation models

were analyzed in TWAS.

Acknowledgements

We are thankful to all participants and the staff at the Rush Alzheimer's Disease Center for making the

proteomics and WGS data of ROS/MAP samples available to the research community. This work was

supported by the National Institute of Health R35GM138313 (T.H., R.P., Q.D., J.Y.). The ROS/MAP

studies are supported by P30AG10161, K01AG054700, R01AG15819, R01AG17917, R01AG56352; the

Illinois Department of Public Health; and the Robert C. Borwell Endowment Fund. The funding

organizations had no role in the design or conduct of the study; collection, management, analysis, or

interpretation of the data; or preparation, review, or approval of the manuscript.

Author contributions

T.H. conducted data analysis and drafted the manuscript. J.Y. conceptualized and led the project, and

edited the manuscript. R.P. and Q.D. contributed to data analysis. A.S.B., S.T., D.A.B., N.T.S.

contributed to ROS/MAP data and edited the manuscript. M.P.E consulted data analysis results and edited

the manuscript.

Data availability

Proteomic, transcriptomic, and WGS data of ROS/MAP samples used in this manuscript are available

from Synapse (https://doi.org/10.7303/syn3219045). These data are available via the AD Knowledge

Portal (https://adknowledgeportal.org), subject to requirements for data access and data attribution as

provided in https://adknowledgeportal.org/DataAccess/Instructions. GWAS summary data of AD

dementia is available from https://ctg.cncr.nl/software/summary_statistics. Results of the pQTL weights

and PWAS summary data generated in this study will be deposited to Synapse after publication of this

work. Instructions for implementing PWAS-O are available through PWAS-O Github page

(https://github.com/tingyhu45/PWAS-O).

Ethics declarations

Both MAP and ROS studies were approved by the Institutional Review Board of Rush University

Medical Center. All individual-level data analyzed in this work were de-identified. Written informed

consent was obtained from all study participants as was an Anatomical Gift Act for organ donation.

ROSMAP resources can be requested at www.radc.rush.edu.

Competing interests

The authors declare no competing interests.

Supplementary information

The supplementary file contains 2 supplementary tables and 8 supplementary figures.

References

1. Wightman, D.P.*, et al.* A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. *Nature genetics* **53**, 1276-1282 (2021).
2. Nagpal, S.*, et al.* TIGAR: An Improved Bayesian Tool for Transcriptomic Data Imputation Enhances Gene Mapping of Complex Traits. *Am J Hum Genet* **105**, 258-266 (2019).
3. Luningham, J.M.*, et al.* Bayesian Genome-wide TWAS Method to Leverage both cis- and trans-eQTL Information through Summary Statistics. *American journal of human genetics* **107**, 714-726 (2020).
4. Tang, S.*, et al.* Novel Variance-Component TWAS method for studying complex human diseases with applications to Alzheimer's dementia. *PLoS genetics* **17**, e1009482 (2021).
5. Gusev, A.*, et al.* Integrative approaches for large-scale transcriptome-wide association studies. *Nature genetics* **48**, 245-252 (2016).
6. Gockley, J.*, et al.* Brain transcriptome wide association study (TWAS) implicates 8 genes across 6 loci in Alzheimer's disease: Genetics: Genetics and omics of AD I. *Alzheimer's & Dementia* **16**, e044839 (2020).
7. Wingo, A.P.*, et al.* Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer's disease pathogenesis. *Nature genetics* **53**, 143-146 (2021).
8. Wingo, T.S.*, et al.* Brain proteome-wide association study implicates novel proteins in depression pathogenesis. *Nat Neurosci* **24**, 810-817 (2021).
9. Zhang, J.*, et al.* Plasma proteome analyses in individuals of European and African ancestry identify cis-pQTLs and models for proteome-wide association studies. *Nat Genet* **54**, 593-602 (2022).
10. Brandes, N., Linial, N. & Linial, M. PWAS: proteome-wide association study-linking genes and phenotypes by functional variation in proteins. *Genome biology* **21**, 173 (2020).
11. Gamazon, E.R.*, et al.* A gene-based association method for mapping traits using reference transcriptome data. *Nature genetics* **47**, 1091-1098 (2015).
12. Zou, H. & Hastie, T. Regularization and variable selection via the elastic net. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)* **67**, 301-320 (2005).
13. Boyle, E.A., Li, Y.I. & Pritchard, J.K. An Expanded View of Complex Traits: From Polygenic to Omnigenic. *Cell* **169**, 1177-1186 (2017).
14. Tibshirani, R. Regression Shrinkage and Selection via the Lasso. *Journal of the Royal Statistical Society. Series B (Methodological)* **58**, 267-288 (1996).
15. Zhou, X., Carbonetto, P. & Stephens, M. Polygenic modeling with bayesian sparse linear mixed models. *PLoS genetics* **9**, e1003264 (2013).
16. Dai, Q.*, et al.* OTTERS: a powerful TWAS framework leveraging summary-level reference data. *Nature Communications* **14**, 1271 (2023).
17. Liu, Y.*, et al.* ACAT: A Fast and Powerful p Value Combination Method for Rare-Variant Analysis in Sequencing Studies. *American journal of human genetics* **104**, 410-421 (2019).
18. Yuan, Z.*, et al.* Testing and controlling for horizontal pleiotropy with probabilistic Mendelian randomization in transcriptome-wide association studies. *Nat Commun* **11**, 3861 (2020).
19. Zhu, Z.*, et al.* Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nat Genet* **48**, 481-487 (2016).
20. Wu, Y.*, et al.* Integrative analysis of omics summary data reveals putative mechanisms underlying complex traits. *Nat Commun* **9**, 918 (2018).

21. Parrish, R.L., Gibson, G.C., Epstein, M.P. & Yang, J. TIGAR-V2: Efficient TWAS tool with
nonparametric Bayesian eQTL weights of 49 tissue types from GTEx V8. *HGG Adv* **3**,
100068 (2022).
22. Bennett, D.A.*, et al.* Religious Orders Study and Rush Memory and Aging Project. *J
Alzheimers Dis* **64**, S161-S189 (2018).
23. Wang, M.*, et al.* The Mount Sinai cohort of large-scale genomic, transcriptomic and
proteomic data in Alzheimer's disease. *Sci Data* **5**, 180185 (2018).
24. Feng, H.*, et al.* Leveraging expression from multiple tissues using sparse canonical
correlation analysis and aggregate tests improves the power of transcriptome-wide
association studies. *PLoS Genet* **17**, e1008973 (2021).
25. De Jager, P.L.*, et al.* A multi-omic atlas of the human frontal cortex for aging and
Alzheimer's disease research. *Scientific data* **5**, 1-13 (2018).
26. Buniello, A.*, et al.* The NHGRI-EBI GWAS Catalog of published genome-wide association
studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res* **47**, D1005-d1012
(2019).
27. Marioni, R.E.*, et al.* GWAS on family history of Alzheimer's disease. *Transl Psychiatry* **8**, 99
(2018).
28. Jansen, I.E.*, et al.* Genome-wide meta-analysis identifies new loci and functional pathways
influencing Alzheimer's disease risk. *Nature genetics* **51**, 404-413 (2019).
29. Kim, S.*, et al.* Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-
tau181p in the ADNI cohort. *Neurology* **76**, 69-79 (2011).
30. Schwartzentruber, J.*, et al.* Genome-wide meta-analysis, fine-mapping and integrative
prioritization implicate new Alzheimer's disease risk genes. *Nature genetics* **53**, 392-402
(2021).
31. Gouveia, C.*, et al.* Genome-wide association of polygenic risk extremes for Alzheimer's
disease in the UK Biobank. *Sci Rep* **12**, 8404 (2022).
32. Davies, G.*, et al.* Study of 300,486 individuals identifies 148 independent genetic loci
influencing general cognitive function. *Nat Commun* **9**, 2098 (2018).
33. Lee, J.J.*, et al.* Gene discovery and polygenic prediction from a genome-wide association
study of educational attainment in 1.1 million individuals. *Nature genetics* **50**, 1112-1121
(2018).
34. Wang, H.*, et al.* Genome-wide interaction analysis of pathological hallmarks in Alzheimer's
disease. *Neurobiol Aging* **93**, 61-68 (2020).
35. Hao, S., Wang, R., Zhang, Y. & Zhan, H. Prediction of Alzheimer's Disease-Associated
Genes by Integration of GWAS Summary Data and Expression Data. *Front Genet* **9**, 653
(2018).
36. Gockley, J.*, et al.* Multi-tissue neocortical transcriptome-wide association study implicates 8
genes across 6 genomic loci in Alzheimer's disease. *Genome Med* **13**, 76 (2021).
37. Gerring, Z., Lupton, M., Edey, D., Gamazon, E. & Derks, E. An analysis of genetically
regulated gene expression across multiple tissues implicates novel gene candidates in
Alzheimer's disease. *Alzheimer's Research & Therapy* **12**, 43 (2020).
38. Sun, Y.*, et al.* A transcriptome-wide association study of Alzheimer's disease using
prediction models of relevant tissues identifies novel candidate susceptibility genes. *Genome
Medicine* **13**, 141 (2021).

39. Davidson, J.E.*, et al.* Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's
disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a
cross-sectional study. *Alzheimers Res Ther* **4**, 51 (2012).
40. Drenos, F.*, et al.* Integrated associations of genotypes with multiple blood biomarkers linked
to coronary heart disease risk. *Hum Mol Genet* **18**, 2305-2316 (2009).
41. Dumont, V. & Lehtonen, S. PACSIN proteins in vivo: Roles in development and physiology.
Acta Physiol (Oxf) **234**, e13783 (2022).
42. Szklarczyk, D.*, et al.* STRING v11: protein–protein association networks with increased
coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic*
Acids Research **47**, D607-D613 (2018).
43. Szklarczyk, D.*, et al.* The STRING database in 2021: customizable protein-protein networks,
and functional characterization of user-uploaded gene/measurement sets. *Nucleic Acids Res*
49, D605-d612 (2021).
44. Jong, M.C., Hofker, M.H. & Havekes, L.M. Role of ApoCs in Lipoprotein Metabolism.
Arteriosclerosis, Thrombosis, and Vascular Biology **19**, 472-484 (1999).
45. Myklebost, O. & Rogne, S. The gene for human apolipoprotein CI is located 4.3 kilobases
away from the apolipoprotein E gene on chromosome 19. *Hum Genet* **73**, 286-289 (1986).
46. Smit, M., van der Kooij-Meijs, E., Frants, R.R., Havekes, L. & Klasen, E.C. Apolipoprotein
gene cluster on chromosome 19. Definite localization of the APOC2 gene and the
polymorphic Hpa I site associated with type III hyperlipoproteinemia. *Human genetics* **78**,
90-93 (1988).
47. Saunders, A.M.*, et al.* Association of apolipoprotein E allele ∈4 with late-onset familial and
sporadic Alzheimer's disease. *Neurology* **43**, 1467-1467 (1993).
48. Panza, F.*, et al.* Lipid metabolism in cognitive decline and dementia. *Brain Res Rev* **51**, 275-
292 (2006).
49. Wood, R.D., Mitchell, M., Sgouros, J. & Lindahl, T. Human DNA repair genes. *Science* **291**,
1284-1289 (2001).
50. Weeda, G.*, et al.* A presumed DNA helicase encoded by ERCC-3 is involved in the human
repair disorders xeroderma pigmentosum and Cockayne's syndrome. *Cell* **62**, 777-791
(1990).
51. Fishel, M.L., Vasko, M.R. & Kelley, M.R. DNA repair in neurons: so if they don't divide
what's to repair? *Mutat Res* **614**, 24-36 (2007).
52. Weissman, L.*, et al.* Defective DNA base excision repair in brain from individuals with
Alzheimer's disease and amnestic mild cognitive impairment. *Nucleic Acids Research* **35**,
5545-5555 (2007).
53. Ajuh, P.*, et al.* Functional analysis of the human CDC5L complex and identification of its
components by mass spectrometry. *Embo j* **19**, 6569-6581 (2000).
54. Urano, Y.*, et al.* Involvement of the mouse Prp19 gene in neuronal/astroglial cell fate
decisions. *J Biol Chem* **281**, 7498-7514 (2006).
55. Yamada, T.*, et al.* The U-box-type ubiquitin ligase PRP19β regulates astrocyte
differentiation via ubiquitination of PTP1B. *Brain Res* **1524**, 12-25 (2013).
56. Lunnon, K.*, et al.* Mitochondrial genes are altered in blood early in Alzheimer's disease.
Neurobiol Aging **53**, 36-47 (2017).
57. Reynolds, C.A.*, et al.* Analysis of lipid pathway genes indicates association of sequence
variation near SREBF1/TOM1L2/ATPAF2 with dementia risk. *Human molecular genetics*
19, 2068-2078 (2010).

58. Verbanck, M., Chen, C.Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy
in causal relationships inferred from Mendelian randomization between complex traits and
diseases. *Nature genetics* **50**, 693-698 (2018).

59. Zhu, Z*., et al.* Integration of summary data from GWAS and eQTL studies predicts complex
trait gene targets. *Nature Genetics* **48**, 481-487 (2016).

60. Barbeira, A.N*., et al.* Exploring the phenotypic consequences of tissue specific gene
expression variation inferred from GWAS summary statistics. *Nature Communications* **9**,
1825 (2018).

61. Wingo, A.P*., et al.* Shared proteomic effects of cerebral atherosclerosis and Alzheimer's
disease on the human brain. *Nature Neuroscience* **23**, 696-700 (2020).

62. The Gene Ontology Resource: 20 years and still GOing strong. *Nucleic Acids Res* **47**, D330-
d338 (2019).

63. Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference
resource for gene and protein annotation. *Nucleic Acids Res* **44**, D457-462 (2016).

64. Jassal, B*., et al.* The reactome pathway knowledgebase. *Nucleic Acids Res* **48**, D498-d503
(2020).

65. UniProt: a worldwide hub of protein knowledge. *Nucleic Acids Res* **47**, D506-d515 (2019).

66. Mungall, C.J*., et al.* The Monarch Initiative: an integrative data and analytic platform
connecting phenotypes to genotypes across species. *Nucleic Acids Res* **45**, D712-d722
(2017).

67. Wu, Y*., et al.* Integrative analysis of omics summary data reveals putative mechanisms
underlying complex traits. *Nature Communications* **9**, 918 (2018).

68. Newman, A.M*., et al.* Robust enumeration of cell subsets from tissue expression profiles.
Nature methods **12**, 453-457 (2015).

69. Darmanis, S*., et al.* A survey of human brain transcriptome diversity at the single cell level.
Proc Natl Acad Sci U S A **112**, 7285-7290 (2015).

70. Wingo, T.S*., et al.* Brain microRNAs associated with late-life depressive symptoms are also
associated with cognitive trajectory and dementia. *NPJ Genom Med* **5**, 6 (2020).

682
683
684

Tables

Table 1. The total number of tested proteins with CV R^2 > 0.005 for the corresponding protein abundance imputation models trained using ROS/MAP reference data by TIGAR, PrediXcan, and FUSION tools. Median CV R^2 of tested proteins are presented in the third column.

Model	Number of Proteins	Median CV R^2
TIGAR	6,673	0.013
PrediXcan	1,835	0.0094
FUSION	2,173	0.0093

Table 2. Independent PWAS-O risk genes of AD dementia. Missing P-values denoted by dashes are due to either CV R^2< 0.5% for the corresponding protein abundance imputation models or no trained protein abundance imputation model by PrediXcan due to variable selection.

Gene	CHR	PWAS-O P-value	TIGAR P-value	PrediXcan P-value	FUSION P-value
CDC42[c]	1	2.47×10^{-4}	2.47×10^{-4}	-	-
ERCC3[b]	2	2.91×10^{-4}	1.80×10^{-4}	-	7.54×10^{-4}
MGAT5	2	6.38×10^{-5}	7.62×10^{-4}	2.19×10^{-5}	2.97×10^{-2}
HSPA1B[b]	6	2.64×10^{-9}	-	-	2.64×10^{-9}
TULP1[b]	6	2.88×10^{-4}	4.14×10^{-1}	-	1.44×10^{-4}
PLA2G7[c]	6	9.03×10^{-5}	9.03×10^{-5}	-	-
MAP3K7	6	5.71×10^{-5}	5.71×10^{-5}	-	-
TRIM4[b]	7	3.72×10^{-5}	3.72×10^{-5}	-	-
AGFG2[a,b,c]	7	9.86×10^{-8}	1.24×10^{-7}	-	8.20×10^{-8}
ZYX[b,c]	7	1.39×10^{-5}	7.91×10^{-6}	5.86×10^{-5}	-
C1QTNF4[b,c]	11	2.24×10^{-5}	2.24×10^{-5}	-	-
MRPL16[b,c]	11	8.66×10^{-15}	4.33×10^{-15}	1.31×10^{-2}	-
CCDC86[b]	11	2.83×10^{-9}	1.42×10^{-9}	-	1.59×10^{-1}
DIABLO	12	9.26×10^{-5}	9.26×10^{-5}	-	-
ATPAF2[b]	17	8.20×10^{-5}	8.20×10^{-5}	-	-
DCAKD[b]	17	6.19×10^{-5}	3.62×10^{-3}	-	3.12×10^{-5}
CLPTM1[a,b,c]	19	1.44×10^{-70}	1.49×10^{-21}	7.21×10^{-71}	-
SPHK2[c]	19	1.76×10^{-4}	4.87×10^{-2}	8.82×10^{-5}	-
YWHAB	20	1.71×10^{-4}	1.71×10^{-4}	-	-

a Known GWAS risk genes of AD dementia.
b Known TWAS risk genes of AD dementia, or test region overlapped with TWAS risk genes.
c Significant mediated causal genetic effects by PMR-Egger or SMR.

Figure titles and legends

Fig.1: Two-stage PWAS framework.
Stage I: Protein abundance imputation models are trained using *cis*-SNPs as predictors and proteomic abundance as the outcome, which estimates pQTL effect sizes (weights) per protein-coding gene. Stage II: Individual PWAS predicts the protein abundances using the trained imputation models and individual-level genotype data of test samples, and then tests the association between the predicted protein abundance and the trait of interest. Summary-based PWAS takes the pQTL effect sizes as variant weights to conduct an equivalent gene-based association test with GWAS Z-scores and reference LD.

Fig. 2: PWAS-O framework.
First, train protein abundance imputation models using reference data and conduct two-stage PWAS (**Fig. 1**) using GWAS data by TIGAR, PrediXcan, and FUSION tools. Second, obtain a PWAS-O p-value per protein-coding gene by aggregating all PWAS p-values by ACAT.

Fig. 3: Test R^2 (A) and PWAS power (B) comparison in simulation studies
Different scenarios with proportions of true causal cis-pQTL $P_{causal} = (0.001, 0.01)$ and protein expression heritability $h_p^2 = (0.01, 0.05)$ were considered in the simulation studies. Boxplots of test R^2 in 50,000 simulations per scenario for 3 PWAS tools were presented (A). Any simulation that was unsuccessful in training protein imputation models would contribute a zero value to the test R^2 score. The median was depicted as a black bar, while the lower and upper hinges represented the 25th and 75th percentiles, respectively. Additionally, the whiskers extended from the hinges to a maximum of 1.5 times the interquartile range. Any data points beyond the whiskers were plotted individually. The power of 50,000 simulations were plotted with respect to various GWAS sample sizes, comparing PWAS-O to 3 PWAS tools (B).

Fig. 4: Manhattan plot of PWAS-O results for AD dementia.
A total of 43 significant risk genes were identified with FDR q-value < 0.05. A total of 19 independently significant genes were labeled. The -log10(q-values) were plotted in y-axis, and -log10(0.05) was plotted as the dashed horizontal line.

Fig. 5: pQTL weights estimated by TIGAR (DPR) and FUSION (best model of LASSO, Elastic-Net, BLUP, Top1) for example significant genes *PPM1N* (A) and *DCAKD* (B) by PWAS-O.
The pQTL weights were plotted in the y-axis for all test SNPs in the test gene region, with color coded with respect to their -log10 (GWAS p-value). SNPs with GWAS p-value < 10^{-5} were plotted in yellow color. Gene *PPM1N* (A) was found significant by both TIGAR and FUSION, as multiple test SNPs with non-zero pQTL weights (by TIGAR and FUSION) were colocalized with significant GWAS SNPs (yellow dots). Whereas, the significance of *DCAKD* (B) was mainly driven by FUSION, for having fewer SNPs with significant GWAS p-values that are also colocalized with a relatively large magnitude of pQTL weights.

Fig. 6: PPI networks and enriched pathways among 43 PWAS risk genes of AD dementia by STRING.
Edges represent physical PPI, with different colors representing different sources of connection evidence. Node colors represent different enriched GO terms or KEGG pathways with FDR < 0.05.

Reference Panel

N samples

SNPs

TTGTCACATG
TACAGACTTG
AGTGTATCGA
ATGTGATAGA
TGTAGTAATT

~

Proteomic Abundance

M proteins

N samples

pQTL Weights (SNP level)

$w_{1,p_1} \ldots w_{l,p_1}$
$w_{1,p_2} \ldots w_{l,p_2}$
$w_{1,p_3} \ldots w_{l,p_3}$
$w_{1,p_m} \ldots w_{l,p_m}$

Individual PWAS

SNPs

TTGTCACATG
TACAGACTTG
AGTGTATCGA
ATGTGATAGA
TGTAGTAATT

Predicted Protein Abundance

Trait

~

Summary-based PWAS

GWAS Z-Scores (SNP-level)

Z_1 Z_2 Z_3 Z_4

Reference LD

Gene-based Association Test by Weighted Sum of GWAS Z-Scores with pQTL Weights and Reference LD

Connections:

- *From curated databases*
- *Experimentally determined*
- *Textmining*
- *Co-expression*
- *Gene fusions*
- *Gene neighborhood*

Enriched pathways

- *UV protection (GO:0009650, FDR = 0.0101)*
- *Adherens junction (hsa04520, FDR = 0.0124)*
- *Transcription-coupled nucleotide-excision repair (GO:0006283, FDR = 0.0131)*
- *Plasma lipoprotein particle remodeling (GO:0034369, FDR = 0.0138)*
- *Negative regulation of very-low-density lipoprotein particle clearance (GO:0043933, FDR = 0.0181)*
- *Protein-containing complex subunit organization (GO:0043933, FDR = 0.0255)*